AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph on Page 11, line 12 to Page 12, line 4 of the specification with the following paragraph:

The specific construction of *trev* is depicted in Figure 1. The first 72 amino acids from HIV 1-Tat with the indicated substitutions were amplified by PCR from the Tat transdominant gene, *tat* 52 –57 using 5′-CGCGCATATGGCAGGAAGAAGCGGAG-3′ (SEQ ID NO:1) as a primer and 5′ -CTAACAGATCTATTCTTTAGCTCCTGACTCCAA-3′ (SEQ ID NO:2) as a 3′ primer. The amplification product was cloned into the *Hinc*II site of pBluescript KS (Stratagene, La Jolla, CA, USA) and sequenced to verify the presence of the desired substitutions. An *Nde*I site was created at the 3′ end of *tat* 52 – 57 for in-frame insertion of *rev*. The 80 –82 deletion in the Rev coding sequence was obtained as an *Nde*I-*Eco*RI fragment in pBR322 and subcloned into *Nde*I-*Eco*RI of the above construct. The final product was sequenced to verify transdominant mutations and in-frame open reading sequences for both *tat* and *rev* portions. An *Rsa*I-*Spe*I fragment containing the *trev* sequence was substituted for Bgal into the *Sma*I-*Xba*I site of pPGK-Bgal. The PGK (phosphoglycerate kinase) promoter has been shown to provide efficient expression in the hematopoietic cell lineage. The Tat 52 –57 expression vector was pDex (RSV-LTR, *tat* 52/57, SV-40 poly A site). The Rev M10 expression vector was pBC12-M10 [cytomegalovirus (CMV)-immediate-early promoter, *Rev-M10*, rat pre-pro insulin intronpoly A site].